• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Gilead Sciences (NQ:GILD)

    131.65 +0.81 (+0.62%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,517,174
    Open 130.00
    Bid (Size) 131.40 (900)
    Ask (Size) 133.10 (200)
    Prev. Close 130.84
    Today's Range 129.01 - 132.36
    52wk Range 95.30 - 157.29
    Shares Outstanding 1,253,809,440
    Dividend Yield 2.40%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    2 Nasdaq 100 Stocks with Solid Fundamentals and 1 We Find Risky
    The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win... 
    Via StockStory

    Performance

    YTD
    +8.3%
    +8.3%
    1 Month
    -6.2%
    -6.2%
    3 Month
    -7.3%
    -7.3%
    6 Month
    +9.9%
    +9.9%
    1 Year
    +27.5%
    +27.5%

    More News

    Read More
    News headline image
    Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish?
    Via Barchart.com
    Topics ETFs
    News headline image
    $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗
    Via Benzinga
    Gilead Sciences Inc (NASDAQ:GILD): A Balanced Dividend Play with Strong Financial Health and Profitability ↗
    Via Chartmill
    Gilead Sciences (NASDAQ:GILD): A Value Screen Candidate with Strong Profitability ↗
    Via Chartmill
    News headline image
    Opes Wealth Sells Its Entire FIXD Stake -- Is This $9.3 Million Bond ETF Exit A Signal? ↗
    Via The Motley Fool
    Topics Bonds ETFs Regulatory Compliance
    News headline image
    U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    3 Healthcare Stocks That Pay You While You Wait for the Growth ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    2 Large-Cap Stocks to Consider Right Now and 1 We Turn Down
    Via StockStory
    News headline image
    Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    What's Going On With Arcus Biosciences Stock On Wednesday? ↗
    Via Benzinga
    News headline image
    Eli Lilly Snags $7 Billion Cancer Deal To Rival Gilead, J&J, Others ↗
    Via Investor's Business Daily
    News headline image
    Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗
    Via Benzinga
    News headline image
    PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    1 Profitable Stock for Long-Term Investors and 2 Facing Challenges
    Via StockStory
    News headline image
    Q4 Earnings Highs And Lows: Gilead Sciences (NASDAQ:GILD) Vs The Rest Of The Therapeutics Stocks
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    Gilead Expands Partnership With Tempus AI To Power Cancer Discoveries ↗
    Via Benzinga
    Topics Artificial Intelligence
    News headline image
    Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis
    Via MarketMinute
    Topics Bonds
    News headline image
    Gilead Expands Tempus AI Partnership To Boost Oncology Pipeline ↗
    Via Benzinga
    Topics Artificial Intelligence
    News headline image
    Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal ↗
    Via Benzinga
    News headline image
    Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
    From Gilead Sciences, Inc.
    Via Business Wire
    News headline image
    Gilead Extends Tender Offer for Arcellx as Biotech M&A Sentiment Faces a Reality Check
    Via MarketMinute
    News headline image
    Gilead Extends Tender Offer to Acquire Arcellx
    From Gilead Sciences, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Gilead Sciences publicly traded?
    Yes, Gilead Sciences is publicly traded.
    What exchange does Gilead Sciences trade on?
    Gilead Sciences trades on the Nasdaq Stock Market
    What is the ticker symbol for Gilead Sciences?
    The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
    What is the current price of Gilead Sciences?
    The current price of Gilead Sciences is 131.65
    When was Gilead Sciences last traded?
    The last trade of Gilead Sciences was at 05/01/26 04:00 PM ET
    What is the market capitalization of Gilead Sciences?
    The market capitalization of Gilead Sciences is 165.06B
    How many shares of Gilead Sciences are outstanding?
    Gilead Sciences has 165B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.